- Home
- ACAD vs AI Comparison
ACAD vs AI Comparison
Compare ACAD & AI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- AI
- Stock Information
- Founded
- ACAD 1993
- AI 2009
- Country
- ACAD United States
- AI United States
- Employees
- ACAD N/A
- AI N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- AI Computer Software: Prepackaged Software
- Sector
- ACAD Health Care
- AI Technology
- Exchange
- ACAD Nasdaq
- AI Nasdaq
- Market Cap
- ACAD 2.5B
- AI 2.9B
- IPO Year
- ACAD 2004
- AI 2020
- Fundamental
- Price
- ACAD $17.44
- AI $23.37
- Analyst Decision
- ACAD Buy
- AI Hold
- Analyst Count
- ACAD 15
- AI 14
- Target Price
- ACAD $24.21
- AI $30.15
- AVG Volume (30 Days)
- ACAD 1.8M
- AI 3.0M
- Earning Date
- ACAD 05-07-2025
- AI 05-28-2025
- Dividend Yield
- ACAD N/A
- AI N/A
- EPS Growth
- ACAD N/A
- AI N/A
- EPS
- ACAD 1.37
- AI N/A
- Revenue
- ACAD $996,283,000.00
- AI $366,923,000.00
- Revenue This Year
- ACAD $13.07
- AI $28.93
- Revenue Next Year
- ACAD $10.06
- AI $21.50
- P/E Ratio
- ACAD $12.74
- AI N/A
- Revenue Growth
- ACAD 22.42
- AI 23.79
- 52 Week Low
- ACAD $13.40
- AI $17.03
- 52 Week High
- ACAD $20.68
- AI $45.08
- Technical
- Relative Strength Index (RSI)
- ACAD 67.70
- AI 60.03
- Support Level
- ACAD $14.45
- AI $21.23
- Resistance Level
- ACAD $15.31
- AI $22.71
- Average True Range (ATR)
- ACAD 0.69
- AI 0.86
- MACD
- ACAD 0.37
- AI 0.33
- Stochastic Oscillator
- ACAD 94.92
- AI 85.62
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About AI C3.ai Inc.
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.